Spruce Biosciences Inc. (SPRB) Dividend Safety Gauge & 10-Year DRIP Compounder

Per the Roarable RQD rating, SPRB scores 42 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars:

• Fundamental Cash Engine (4 / 20): The lowest-scoring pillar, reflecting ROIC of -35% and an FCF yield of -24.77%. For a prospective investor, this indicates the business is currently consuming cash rather than generating it, so any valuation rests on future outcomes not yet visible in reported cash flows.
• Whale 13F Flow (9 / 20): Institutional accumulation and options positioning are scored below midpoint. Holder-level detail is not available in source data, so the score cannot be decomposed further here.
• Insider Conviction (5 / 20): Per the RQD rating, SEC Form 4 and Congressional PTR cluster flow scored weakly. Investors should treat this as a limited signal of management or insider confidence.
• Macro Regime Fit (14 / 20): With beta of 1.0 and sector sensitivity, the stock's market sensitivity is neutral-to-moderate rather than defensive.
• Forensic Balance Sheet (10 / 20): Altman Z of 0.2, Piotroski F of 4/9, and Debt/Equity of 0.5 point to financial fragility. A low Altman Z in particular signals elevated distress risk under the source's framework.

Implications: Upside drivers would need to come from catalysts that convert pipeline activity into cash generation, which the cash-engine and balance-sheet pillars do not yet demonstrate. Valuation tradeoffs are significant: with negative ROIC and FCF yield, conventional earnings multiples are unavailable, so value depends on forward assumptions the source data does not quantify. This is an educational read of the rating, not personalized advice.

Spruce Biosciences Inc. (SPRB) is a NASDAQ-listed company in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry, per the company profile. Per the recent news catalysts, the company is associated with MPS IIIB natural history data, indicating a focus on rare disease research. Customers, product revenue mix, and monetization model are not available in source data.

Per the SEC financials, revenue declined from $10.1M (FY 2023) to $4.9M (FY 2024) to $0.0M (FY 2025), while net losses persisted across all three periods. Gross, operating, and net margins are reported as 0% in the market data, and ROIC is -35%. The Altman Z-Score is 0.2 and the Piotroski F-Score is 4/9, both per the Roarable RQD forensic balance sheet pillar. Cash of $48.9M against debt of $0.0M in FY 2025 indicates a net cash position on the reported figures, while the Debt/Equity ratio is cited as 0.5.

Per the recent news catalysts feed:

• Conference participation: Spruce Biosciences to participate in the Craig-Hallum Biotech Catalyst Conference (YELLOW light, market wire).
• Analyst action: B.Riley reiterated a Buy rating with a $160 target (YELLOW light, market wire). This is a single third-party reference; the price target is far above the $46.82 price and the reliability of this figure is not corroborated elsewhere in the source data.
• Clinical data presentation: MPS IIIB natural history data to be presented at the 55th Child Neurology Society Annual Meeting (YELLOW light, market wire).
• Price action: A report describes a 3.87% rally to $41.97 as shares pressed toward the upper range. This headline conflicts with the current price of $46.82 and should be treated with caution given differing timestamps.

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. All catalysts carry a YELLOW light classification.

• What is the company's pipeline status, and what clinical or regulatory milestones define the path to revenue?
• What drove the decline in revenue from $10.1M to $0.0M, and is any collaboration or licensing income expected?
• What is the cash runway given FY 2025 FCF of $-33.3M against cash of $48.9M?
• Who are the major institutional holders, and how has their positioning changed?
• Why do the news headlines cite prices ($41.97) and analyst targets ($160) that differ materially from the current price and the source's data?